Key result
Botulinum toxin A improves arm function and range of motion after stroke without reducing grip strength.
To determine the functional benefit of botulinum toxin A (BtxA) in spasticity of arm flexors, we conducted an open-label study with 10 stroke patients. 480 mouse units BtxA (Dysport((R))) were injected into flexor muscles. Outcome measures were done by the Modified Ashworth Scale, Rivermead Motor Assessment (arm section), active and passive ranges of motion (ROM), grip strength and a 3-dimensional motion analysis. The functional capacity of the entire arm, even of the shoulder, and the ROM of fingers and wrist increased. Despite a diminution of muscle tone, grip strength remained unchanged or increased. An improvement of forearm extension was only observed in cases of preserved voluntary extensor motricity. Injection of BtxA into spastic distal flexor muscles may lead to a functional improvement of the entire arm. Grip strength is not necessarily reduced.
No takes yet. Share an insight, caveat, or question.
Woldag et al. (2003) studied Spasticity of arm flexors following stroke (n=10). Botulinum toxin A (Dysport) was evaluated on Modified Ashworth Scale, Rivermead Motor Assessment (arm section), active and passive ranges of motion (ROM), grip strength, and 3-dimensional motion analysis. Botulinum toxin A (480 mouse units) injected into spastic arm flexors of 10 stroke patients increased arm functional capacity and finger/wrist ROM without reducing grip strength.
Synapse has enriched 5 related papers. Consider them for comparative context: